Generate Biomedicines director proposes $185K sale

The notice also lists two common-stock sales during the prior three months: 1,000 shares on September 1, 2026, and 32,210 shares on September 2, 2026.

Rhea-AI Filing Summary

Frances Arnold, a director of Generate Biomedicines, Inc. (GENB), reported a proposed sale of 11,409 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $184,732.91 and an approximate sale date of October 29, 2026. The notice identifies the shares as acquired through restricted stock vesting on September 23, 2020.

Key Figures

Proposed sale: 11,409 common shares Aggregate market value: $184,732.91 Prior sale: 1,000 common shares +3 more

6 metrics

Proposed sale 11,409 common shares Approximate sale date: October 29, 2026

Aggregate market value $184,732.91 Proposed sale of 11,409 common shares

Prior sale 1,000 common shares September 1, 2026

Prior sale value $16,002.00 September 1, 2026

Prior sale 32,210 common shares September 2, 2026

Prior sale value $520,630.62 September 2, 2026

Key Terms

Rule 144, restricted stock vesting, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GENB shares did Frances Arnold propose to sell?

Frances Arnold, a director of Generate Biomedicines, Inc. (GENB), reported a proposed sale of 11,409 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $184,732.91 and an approximate sale date of October 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/29/2026 - 04:12 PM EDT Accepted by SEC EDGAR 10/29/2026 - 04:12 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001665419
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Generate Biomedicines, Inc.
SEC File Number	001-43165
Address of Issuer	101 SOUTH STREET, SUITE 900 SOMERVILLE MASSACHUSETTS 02143
Phone	888-469-0055
Name of Person for Whose Account the Securities are To Be Sold	ARNOLD FRANCES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	11409	184732.91	128352436	10/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/23/2020	Restricted Stock Vesting	Issuer			11409	09/23/2020	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Frances Arnold 101 South Street Suite 900 Somerville MA 02143	Common	09/01/2026	1000	16002.00
Frances Arnold 101 South Street Suite 900 Somerville MA 02143	Common	09/02/2026	32210	520630.62

144: Remarks and Signature

Remarks
Date of Notice	10/29/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Frances Arnold
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)